Position in CLLS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$2,992
-$10,371 QoQ
Shares Held
944
-65.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
6 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in CLLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026QUADRANT CAPITAL GROUP LLC holds $22,161,348 across 129 Biotechnology names. CLLS ranks #96 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,677 | $2,840,997 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,716 | $2,552,422 | |
| 3 | ARGX |
Argenx SE
|
2,778 | $2,028,634 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
2,605 | $1,363,639 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
49,144 | $1,361,288 | |
| 6 | EXEL |
Exelixis, Inc.
|
28,474 | $1,221,249 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
20,772 | $1,173,410 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
5,659 | $1,129,819 |
All Filings in CLLS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,992 | 944 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $13,363 | 2,761 | Shares | Sole | 2026-02-13 | |
| 2022-03-31 | $4,703 | 1,036 | Shares | Sole | 2022-05-06 | |
| 2021-12-31 | $15,168 | 1,868 | Shares | Sole | 2022-02-01 | |
| 2021-09-30 | $11,878 | 942 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $10,736 | 694 | Shares | Sole | 2021-08-09 | |
| No filing history on record for this holder in this stock. | ||||||